Year in Review: Top 20 reimbursed medicines by gross spend

Rank Medicine Therapeutic Group 2019/20
      $
1 Glecaprevir and pibrentasvir (Maviret) Antivirals $129,320,000
2 Adalimumab Immunosuppressants $98,720,000
3 Dabigatran Antithrombotic Agents $45,480,000
4 Pembrolizumab Immunosuppressants $42,160,000
5 Trastuzumab Immunosuppressants $35,740,000
6 Insulin glargine Diabetes $34,150,000
7 Pneumococcal vaccine Vaccinations $33,300,000
8 Etanercept Immunosuppressants $30,910,000
9 Human papillomavirus (6, 11, 16, 18,
31, 33, 45, 52 and 58) vaccine [HPV]
Vaccinations $26,300,000
10 Abiraterone acetate Oncology $25,450,000
11 Lenalidomide Oncology $25,370,000
12 Budesonide with eformoterol Respiratory $24,970,000
13 Diphtheria, tetanus, pertussis,
polio, hepatitis B and haemophilus
influenzae type B vaccine
Vaccinations $23,120,000
14 Fluticasone with salmeterol Respiratory $23,040,000
15 Rurioctocog alfa pegol
[Recombinant factor VIII]
Blood & Blood Forming Organs $21,860,000
16 Rituximab Immunosuppressants $18,540,000
17 Rivaroxaban Antithrombotic Agents $16,790,000
18 Dolutegravir Anti-infectives $16,470,000
19 Paliperidone Anti-psychotics $15,400,000
20 Aflibercept Immunosuppressants $15,170,000
    Totals $702,260,000

The data above excludes hospital purchases.

Gross spend is shown in millions NZD, is exclusive of GST, and prior to the application of rebates and discounts.

This data can change as prior year adjustments are made.

(1) This figure is based on the listed price and estimated units at dispensing.